Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

27
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
27
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

4
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
4
Subviral Agents01:29

Subviral Agents

723
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
723
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

7
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
7
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis.

The American journal of gastroenterology·2026
Same author

HBx interacts with the host YBX3 protein and up-regulates its expression to mediate efficient Hepatitis B viral replication.

Frontiers in cellular and infection microbiology·2026
Same author

Identification of Cyclin L1 as a Host Factor Regulating Hepatitis B Virus Replication.

Viruses·2026
Same author

SEVERE HEPATITIS B FLARE AND LIVER FAILURE - CURRENT ASSESSMENT AND MANAGEMENT.

Clinical and molecular hepatology·2026
Same author

Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Time for a globally unified chronic HBV terminology?

JHEP reports : innovation in hepatology·2025

Related Experiment Video

Updated: Mar 22, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Time for Action on Viral Hepatitis.

Seng Gee Lim1

  • 1Division of Gastroenterology and Hepatology, National University Health System, Singapore.

Annals of the Academy of Medicine, Singapore
|April 28, 2016
PubMed
Summary

Viral hepatitis outbreaks underscore the need for robust infection control. New therapies offer high cure rates for Hepatitis C virus (HCV), while advancements in Hepatitis B virus (HBV) treatment aim to prevent liver failure.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Viral hepatitis, particularly Hepatitis C virus (HCV) and Hepatitis B virus (HBV), poses significant public health risks, as evidenced by recent outbreaks.
  • HCV outbreaks highlight the critical role of infection control and environmental contamination in disease transmission.
  • While HBV vaccination has reduced prevalence, complications like HBV flares and liver failure remain concerns, especially in undiagnosed or lost-to-follow-up patients.

Purpose of the Study:

  • To review the current landscape of viral hepatitis management, focusing on recent therapeutic advancements and persistent challenges in identification and linkage to care.
  • To emphasize the importance of proactive screening and treatment in at-risk populations to prevent outbreaks and improve patient outcomes.
  • To highlight ongoing research initiatives aimed at achieving a cure for HBV.

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Experiment Videos

Last Updated: Mar 22, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Main Methods:

  • Review of recent developments in antiviral therapies for HCV and HBV.
  • Discussion of infection control measures and their impact on preventing viral hepatitis outbreaks.
  • Analysis of patient management strategies, including screening, diagnosis, and linkage to care for viral hepatitis.

Main Results:

  • Direct-acting antiviral (DAA) therapy has revolutionized HCV treatment, achieving high cure rates (90-100%) in short treatment durations (12 weeks).
  • Effective antiviral therapies exist for HBV, but challenges in patient identification and consistent follow-up contribute to severe complications like liver failure.
  • A significant number of patients requiring liver transplantation for HBV-related liver failure have died awaiting the procedure due to delayed diagnosis or lack of follow-up.

Conclusions:

  • Treating HCV in high-risk groups can mitigate future outbreaks and reduce the overall burden of the disease.
  • Improved strategies for identifying HBV-infected individuals and ensuring their linkage to care are crucial to prevent avoidable liver failure and deaths.
  • Ongoing research and national initiatives are paving the way for potential cures for HBV.